Sacituzumab Tirumotecan and Tagitanlimab for aggressive prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two drugs for men with aggressive or neuroendocrine prostate cancer that has worsened after previous hormone therapy. The goal is to see if the combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with aggressive variant or neuroendocrine prostate cancer.
- You have tried one or two second-generation anti-androgen therapies, and may have had docetaxel, but no other chemotherapy.
- Your cancer has progressed in the last 6 months, shown by a rise in PSA or new lesions on scans.
- You are willing to stay on a LHRH agonist (if you have not had surgery to remove testicles).
- You have at least one measurable tumor that has not been treated with radiation, and your cancer is not only in skin or bone.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (docetaxel) and a targeted radiation therapy (lutetium-PSMA) as a first treatment for men whose prostate cancer has spread and no longer responds to hormone therapy. The goal is to see if this combination is safe and effective.
This trial tests a combination of two drugs—an antibody-drug conjugate that targets a protein on cancer cells and an immunotherapy that helps your immune system attack the tumor—for people with advanced triple-negative breast cancer that has already been treated. It aims to see if this combo can shrink tumors or slow the disease.
This trial tests sacituzumab tirumotecan, a new targeted drug designed to treat neuroendocrine prostate cancer (a rare, aggressive type) in patients whose cancer has progressed despite prior chemotherapy. The drug works by targeting cancer cells and delivering a poison directly to them.
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
This trial tests a combination of two drugs, sacituzumab tirumotecan and tagitanlimab, for people with advanced esophageal or stomach cancer that has worsened after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.